Loading...
•
Sep 30, 2024
Checkpoint Therapeutics Q3 2024 Earnings Report
Reported third quarter 2024 financial results and recent corporate updates.
Key Takeaways
Checkpoint Therapeutics reported financial results for the third quarter ended September 30, 2024. The company awaits the FDA decision on its BLA resubmission for cosibelimab with a PDUFA goal date set for next month. $9.2 million in cash proceeds received from the exercise of existing warrants has strengthened the balance sheet to extend beyond the PDUFA date and into 2025.
Awaiting FDA decision on Biologics License Application (BLA) resubmission for cosibelimab.
PDUFA goal date is set for December 28, 2024.
Received $9.2 million in cash proceeds from the exercise of existing warrants.
Focusing on preparing for the potential approval of cosibelimab.
Forward Guidance
The company is preparing for the potential approval of cosibelimab and looks forward to potentially offering oncologists a new, differentiated treatment option for patients with advanced cutaneous squamous cell carcinoma.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...